Center for Stem Cell and Translational Immunotherapy

Dual Stem Cell Therapy Shows Promise for Treating Leptomeningeal Brain Metastasis (LBM) in lung cancer ? Our latest work published in the JNCI unveils a promising new treatment strategy for leptomeningeal brain metastasis (LBM), a devastating complication of cancers like NSCLC. We developed a dual stem cell therapy that delivers oncolytic herpes simplex virus (oHSV) that directly targets and destroys cancer cells and immune checkpoint inhibitor (scFvPD-1) which unleashes the body's own immune system to fight the tumor. A powerful one-two punch against LBM tumors!! In advanced preclinical models, this dual-pronged approach significantly improved survival rates and showcased a remarkable ability to: ??Induce immunogenic cell death ? Activate anti-tumor T cell signaling ? Disrupt tumor metabolism, enhancing sensitivity to chemotherapy This breakthrough offers renewed hope for patients with LBM, a disease with historically limited treatment options. Our team is excited to advance this research towards clinical trials and ultimately bring this innovative therapy to those in need. Congratulations to Dr. Shah and the entire research team at CSTI for their dedication and hard work in advancing cancer treatment! Nobu Kanaya Waleed Seddiq Kok Siong Chen Lucía Moreno Lama, Ph.D Paulo Borges Hiroaki Wakimoto Khalid Shah MGB Innovation MGB Research MGB Neurosurgery MGB Research Link to publication: https://lnkd.in/dtYDPbqN Link to press release: https://lnkd.in/d7rkefVe #BrainTumorAwareness #CancerResearch #StemCellTherapy #Immunotherapy #PrecisionMedicine #NeuroOncology #clinicaltrials #NSCLC

Turning Cancer Cells into Cancer Killers: A Safer, More Effective Approach ?? We've developed and optimized a "therapeutic safety switch" for cancer cell-based therapies that boosts the immune system's ability to fight tumors and enhances safety. This new technology, featuring the RIPK3-driven necroptosis, allows us to precisely eliminate engineered cancer-killing cells after they've served their purpose, while stimulating a powerful anti-tumor immune response. Our research, published in the Journal of Clinical Investigation, demonstrated significant improvements in tumor suppression, survival rates, and long-term immunity in preclinical models. This breakthrough can potentially revolutionize cancer treatment and could be applied to other cell-based therapies beyond cancer. A huge congratulations to Dr. Shah and the entire research team at CSTI for their dedication and innovation in advancing cancer treatment! ?? Khalid Shah Kok Siong Chen Sarah Manoury Nobu Kanaya Ioulita Vogiatzi Paulo Borges Sterre Kruize Yi-Ching Chen Filippo Rossignoli Natalia Mendonca Publication link: https://lnkd.in/erYjtGtU Press release link: https://lnkd.in/enendrdx #cancerresearch #celltherapy #immunotherapy #innovation #MassGeneralBrigham #CSTI #HarvardMedicalSchool #HarvardStemCellInstitute